A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers

scientific article published on 12 January 2017

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1172/JCI.INSIGHT.89760
P932PMC publication ID5214535
P698PubMed publication ID28097235

P50authorMeenhard HerlynQ16732421
Gordon B. MillsQ28086262
Clemens KreplerQ61529607
Robert H MachQ88117640
Patricia BraffordQ125315151
Brandon WenzQ125342093
Katherine L NathansonQ37369859
P2093author name stringMark Morgan
Neil Johnson
Ronny Drapkin
Yiling Lu
Eric Brown
Ying Zheng
Fiona Simpkins
Hyoung Kim
George Cotsarelis
Robert Soslow
Mehran Makvandi
Rugang Zhang
Janos L Tanyi
Erin George
Xiaochen Zhang
Stephanie Jean
P2860cites workComparison of established cell lines at different passages by karyotype and comparative genomic hybridizationQ23921272
Patient-derived tumour xenografts as models for oncology drug developmentQ24604068
Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugsQ24610287
Emerging and Evolving Ovarian Cancer Animal ModelsQ26783909
Maintaining Tumor Heterogeneity in Patient-Derived Tumor XenograftsQ26801063
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian CancerQ26801525
Integrated genomic analyses of ovarian carcinomaQ27860518
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyQ27860519
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseQ28131711
Phenotypic instability of Saos-2 cells in long-term cultureQ28254879
ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assaysQ28364520
Fast and accurate long-read alignment with Burrows-Wheeler transformQ29547193
SIFT: Predicting amino acid changes that affect protein functionQ29547211
A framework for variation discovery and genotyping using next-generation DNA sequencing dataQ29547262
Cancer statistics, 2016Q29547383
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short readsQ29617402
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancerQ29620068
The microenvironment of the tumour-host interfaceQ29620375
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerQ30409503
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakageQ31160033
Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.Q33607384
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53.Q33661151
Establishment of human tumor xenografts in immunodeficient miceQ34003315
Patient-derived xenograft models in gynecologic malignanciesQ34141193
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendationsQ34200152
Patient-derived xenograft models: an emerging platform for translational cancer researchQ34205518
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent mannerQ34676703
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomasQ34998940
Cell cycle-related proteins p21 and bcl-2: markers of differentiation in the human fallopian tubeQ74081573
Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential modelsQ81120942
ATR prohibits replication catastrophe by preventing global exhaustion of RPA.Q35051406
Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factorsQ35105456
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesQ35212640
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATRQ35640593
Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.Q35736188
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.Q35758403
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumoursQ35759295
The promise and challenge of ovarian cancer modelsQ35771750
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S PhaseQ36075291
CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiationQ36280773
It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.Q36436803
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancerQ36568348
Chk1 and Claspin potentiate PCNA ubiquitinationQ36585485
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian CancerQ36586093
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.Q36908567
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.Q36941455
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoQ36974565
Evaluating cell lines as tumour models by comparison of genomic profilesQ37025950
ATR phosphorylates SMARCAL1 to prevent replication fork collapseQ37064611
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profilingQ37395388
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancerQ37438981
Advanced cytoreductive surgery: American perspectiveQ37539178
Tumorgrafts as in vivo surrogates for women with ovarian cancer.Q37626455
Epithelial ovarian cancer experimental models.Q37708938
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?Q38165720
Molecular Pathways: Targeting ATR in Cancer TherapyQ38585436
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.Q39282659
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.Q39559122
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cellsQ40220260
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.Q41316932
Characterization of a novel ATR-dependent, Chk1-independent, intra-S-phase checkpoint that suppresses initiation of replication in XenopusQ41846285
wANNOVAR: annotating genetic variants for personal genomes via the web.Q42129589
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinomaQ46390942
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.Q52851743
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.Q53263238
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationQ56240758
P4510describes a project that usesImageJQ1659584
P433issue1
P921main subjectovarian cancerQ172341
xenograftQ64148587
P304page(s)e89760
P577publication date2017-01-12
P1433published inJCI insightQ27727187
P1476titleA patient-derived-xenograft platform to study BRCA-deficient ovarian cancers
P478volume2

Reverse relations

cites work (P2860)
Q52430620A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Q91820897An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer
Q92476256Applications of patient-derived tumor xenograft models and tumor organoids
Q92214119CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies
Q55261818Chromosomal inversions as a hidden disease-modifying factor for somatic recombination phenotypes.
Q97692537Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Q64969004Current Status of Patient-Derived Ovarian Cancer Models.
Q88875414Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
Q47107803Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Q98777898Human-Derived Model Systems in Gynecological Cancer Research
Q89471826MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Q48124146Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
Q92126687Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Q61812758Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Q52811875Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.
Q90254910Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
Q91698737Xenograft and organoid model systems in cancer research

Search more.